Arcus Biosciences (RCUS) Liabilities and Shareholders Equity (2017 - 2026)
Arcus Biosciences (RCUS) posted quarterly Liabilities and Shareholders Equity of $997.0 million for Q1 2026, down 16.92% year-over-year from $1.2 billion in Q1 2025, and down 12.47% quarter-over-quarter from $1.1 billion in Q4 2025.
Arcus Biosciences (RCUS) Liabilities and Shareholders Equity (2017 - 2026) Analysis & Trends
Arcus Biosciences' Liabilities and Shareholders Equity history runs 10 years deep, the most recent figure standing at $997.0 million for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity fell 16.92% year-over-year to $997.0 million; the TTM figure through Mar 2026 stood at $4.2 billion (down 13.71% YoY), while the FY2025 annual figure was $1.1 billion, down 0.96% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $997.0 million, down from $1.1 billion in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $1.5 billion in Q1 2022, with the low at $974.0 million in Q3 2025.
- The 5-year median for Liabilities and Shareholders Equity is $1.2 billion (2024), against an average of $1.2 billion.
- The sharpest annual moves came in 2022 and 2025: Liabilities and Shareholders Equity surged 66.07% in 2022, then decreased 25.08% in 2025.
- Arcus Biosciences' Liabilities and Shareholders Equity stood at $1.3 billion in 2022, then dropped by 15.77% to $1.1 billion in 2023, then rose by 5.02% to $1.2 billion in 2024, then declined by 0.96% to $1.1 billion in 2025, then slipped by 12.47% to $997.0 million in 2026.
- Business Quant data shows RCUS's Liabilities and Shareholders Equity at $997.0 million in Q1 2026, $1.1 billion in Q4 2025, and $974.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Arcus Biosciences | 3.74 Bn | 3.04 Bn | - | 924.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 924.00 Mn |
| Mar 31, 2026 | 997.00 Mn |
| Dec 31, 2025 | 1.14 Bn |
| Sep 30, 2025 | 974.00 Mn |
| Jun 30, 2025 | 1.08 Bn |
| Mar 31, 2025 | 1.20 Bn |
| Dec 31, 2024 | 1.15 Bn |
| Sep 30, 2024 | 1.30 Bn |
| Jun 30, 2024 | 1.20 Bn |
| Mar 31, 2024 | 1.30 Bn |
| Dec 31, 2023 | 1.10 Bn |
| Sep 30, 2023 | 1.19 Bn |
| Jun 30, 2023 | 1.22 Bn |
| Mar 31, 2023 | 1.25 Bn |
| Dec 31, 2022 | 1.30 Bn |
| Sep 30, 2022 | 1.39 Bn |
| Jun 30, 2022 | 1.48 Bn |
| Mar 31, 2022 | 1.54 Bn |
| Dec 31, 2021 | 1.59 Bn |
| Sep 30, 2021 | 839.29 Mn |